

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 10, 2022**

IsoPlexis Corporation

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-40894

(Commission
File No.)

46-2179799
(IRS Employer
Identification No.)

35 NE Industrial Road, Branford, CT 06405
(Address of principal executive offices and zip code)
(203) 208-4111
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ISO	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, Isoplexis Corporation (the "Company") issued a press release reporting its preliminary unaudited financial revenue for the year ended December 31, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

Beginning on January 10, 2022, ancillary to the 40th Annual J.P. Morgan Healthcare Conference, the Company will be meeting with certain analysts and investors and will be providing a presentation (“Investor Presentation”) to such analysts and investors, discussing, among other topics, an overview of the Company’s business and growth strategy. A copy of the Investor Presentation, which is available at www.isoplexis.com, is being furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

The information furnished with this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of IsoPlexis Corporation, dated January 9, 2022
99.2	Isoplexis Investor Presentation, dated January 10, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOPLEXIS CORPORATION

Date: January 10, 2022

By: /s/ John Strahley
Name: John Strahley
Title: Chief Financial Officer

IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library

Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum

BRANFORD, Conn., Jan. 9, 2022, (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the full year 2021. Total revenue for 2021 is expected to be in the range of \$17.0 to \$17.2 million, representing an increase of approximately 64% to 66% compared to \$10.4 million for the full year 2020.

Since the commercial launch in 2018, IsoPlexis has placed 209 total instruments, including 98 new instruments sold during 2021. As of year end, IsoPlexis passed an important milestone with 67% of US comprehensive cancer centers and in addition, 100% of the top 15 pharma now using IsoPlexis for functional cell analysis.

IsoPlexis also today unveiled The Superhuman Cell Library, an industry-first mapping of the proteomically driven cells, unique to IsoPlexis' platform, that determine how the human body responds to complex disease. By identifying a comprehensive range of rare but important super cells, the library categorizes how these cells have been used to predict patient response to therapies in a wide range of clinically relevant journals. The library also lays the groundwork for customers to continue to add on to the characterization of these uniquely predictive cells to advance all of human health.

"Our 2021 revenue growth reinforces the value of our platform and how, together with the release of The Superhuman Cell Library, IsoPlexis is taking a lead in advancing the future of medicine and health," said IsoPlexis Chief Executive Officer Sean Mackay. "The IsoPlexis platform allows researchers to uncover superhero cells and superhuman biology for the first time, unlocking unprecedented insights into the development of therapies for the world's toughest diseases."

These preliminary results are based on management's initial analysis of operations for the quarter that ended on December 31, 2021. The company expects to issue full financial results for the fourth quarter and full year 2021 in late February 2022.

The Superhuman Cell Library provides a comprehensive definition of proteomically driven cells that is leading to major advances in the way illnesses are diagnosed and treated. It is a valuable resource across oncology, immunology, infectious diseases, neurology, inflammatory diseases, and cell and gene therapies. It is available now as an industry-wide, literature-referenced, and consistently updated resource at <http://isoplexis.com/FCL>.

"Following the releases of the Human Cell Atlas and the Human Genome Atlas, definitions of the functional proteome from each cell are critical to moving forward our understanding of human cell behavior. By mapping our body's most functionally active immune cells, or cell "superheroes", IsoPlexis is making a key contribution to furthering our understanding of the power of each single cell in the human body," said James R. Heath Ph.D. Dr. Heath is President and Professor at the Institute for Systems Biology in Seattle, and a Professor of Bioengineering at the University of Washington. He also co-founded and is a member of the IsoPlexis scientific advisory board.

About IsoPlexis

IsoPlexis is the Superhuman Cell company.

IsoPlexis' systems uniquely identify a comprehensive range of multifunctional single cells, i.e. the superhero cells in the human body. These cells enable researchers to understand and predict disease progression, treatment resistance and therapeutic efficacy to advance all of human health.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at two-thirds of leading U.S. comprehensive cancer centers.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies and other future conditions. Such forward-looking statements may include, without limitation, statements about future opportunities for us and our products and services, our future operations, financial or operating results, including our financial guidance, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions and other expectations and targets for future periods. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “seek,” “will,” “would,” “could,” “should,” “continue,” “contemplate,” “plan,” and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them.

Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, among others, the following: estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs for additional financing; the implementation of our business model and strategic plans for our products and technologies; competitive companies and technologies and our industry; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to develop and commercialize new products; our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement; the performance of third party suppliers; our ability to hire and retain key personnel and to manage our future growth effectively; our ability to obtain additional financing in future offerings; the volatility of the trading price of our common stock; our expectations regarding use of proceeds from our initial public offering (“IPO”); the potential effects of government regulation; the impact of COVID-19 on our business; and our expectations about market trends. For a further discussion of these and other factors that could impact our future results, performance or transactions, see the section “Risk Factors” included in our Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 12, 2021, and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. We qualify all of the forward-looking statements in this press release by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contactinvestors@isoplexis.com**Press Contact**press@isoplexis.com**Related Links**www.isoplexis.com



The Superhuman Cell Company

January 2021



Disclaimer and Forward-Looking Statements

IsoPlexis Corporation ("IsoPlexis," "we," "us," or the "Company") has filed a prospectus on Form S-1 (File No. 333-258046) with the SEC for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the preliminary prospectus in that registration statement and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting the SEC website at <http://www.sec.gov>. Alternatively, copies of the prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 190 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 646-718-1649 or by email at prospectus@morganstanley.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; Evercore Group, L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, via telephone at 1-888-474-0200, or via email at ecm.prospectus@evercore.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at syndicate@svbleerink.com. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Confidential information

This presentation is being provided solely for your confidential use with the express understanding that you will not release any portion of this document, discuss the information contained herein, or make reproductions of or use this presentation for any other purpose without the prior express written permission of the Company. By reviewing this information, you are acknowledging the confidential nature of this information and are agreeing to abide by the terms of this legend.

Forward-looking statements and other information

This presentation contains forward-looking statements about the Company. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies and other future conditions. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "seek," "will," "would," "could," "should," "continue," "contemplate," "plan" and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this presentation, as disclosed in the "Risk Factors" and "Special Note Regarding Forward-Looking Statements" sections of our prospectus and quarterly report on Form 10-Q filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them.

All information contained herein speaks only as of the date of this presentation, except where information is stated to be presented as of a specific date. The Company undertakes no duty to update or revise the information contained herein, publicly or otherwise, including any forward-looking statements.

Market, Industry and Other Data

This presentation includes estimates regarding market and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our general expectations, market position, market opportunity and market size, are based on our management's knowledge and experience in the markets in which we operate, together with currently available information obtained from various sources, including publicly available information, industry reports and publications, surveys, our customers, trade and business organizations and other contacts in the markets in which we operate. Certain information is based on management estimates, which have been derived from third-party sources, as well as data from our internal research. In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets in which we operate. Market and industry data, which is derived in part from management's estimates and beliefs, are subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process and other limitations inherent in any statistical survey of such data. In addition, projections, assumptions and estimates of the future performance of the markets in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in "Risk Factors" and "Special Note Regarding Forward-Looking Statements" of the registration statement. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.

Trademarks

Each trademark, trade name or service mark of any other company appearing or incorporated by reference in this presentation belongs to its holder. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, such other companies.

Non-GAAP Financial Measures This presentation includes certain non-GAAP financial measures, including EBITDA. Such non-GAAP financial measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. A reconciliation of these measures to the most directly comparable GAAP measure is included in the Appendix to these slides.

**WE LEVERAGE THE
SUPERHUMAN CELLS IN ALL OF
US TO CHANGE THE COURSE
OF HUMAN HEALTH**






Large opportunity to change the course of human health as **The Superhuman Cell Company**
Platform impact encompasses **3 sequential TAMs totaling \$34B**²

209 instruments in the field¹
64-66% YTD revenue growth through Q4 2021³
98 Publications leveraging superhuman cells to fight complex diseases


Instruments placed in **two-thirds of Comprehensive Cancer Centers in the US**⁴ and **All of the Top 15 Pharma**⁵

¹ As of Q4 2021. ² Based on management estimates.
³ Preliminary unaudited 2021 full year revenue. ⁴ Based on the National Cancer Institute's list of Comprehensive Cancer Centers ⁵ By 2020 revenue.

Three Disconnected Paradigms Changing Biology & Medicine



IsoPlexis' Superhero Cells Connect These Three Paradigms



Why Proteome is Critical to Superhero Cells

Single cell genomics misses key proteomic activity... is an indirect indicator (i.e. the blueprint)



TRANSCRIPTOME

Low correlation (0.4)* between transcription/RNA and proteomic cell function


Clinical activity in human health dictated by direct proteome activity



PROTEOME

*Vogel et al. Nature Reviews Genetics, 2012

IsoPlexis' Unique Superhero Cells are Key to Fighting Cancer




IsoPlexis reveals highly proteomically "multi-functional" superhero immune cells

Presence of these cells are key predictors of early and persistent response to cancer *

* Representative of high impact publications. Ref: Diab et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology. 2021.

Superhero cells are advancing the fight against many critical diseases



Superhero and supervillain cells play key predictive role

Revealing superhero cells in the proteomics landscape

Cell type (Flow cytometry and single cell genomics) vs IsoPlexis' superhero cell function




Surface markers (flow cytometry and single cell genomics) hides true identity




Multiplexed cytokines reveal the unique power of the individual super cell ie: Secret identity

Wave of Bulk Proteomics Drives Need for Single Cell Proteomics



Critical, Unique Use Cases Supported In Many High Impact Journals

Cell and Gene Therapy



Superhero cells make the best products for clinical response

Cancer immunology



Superhero cells show which patients respond durably to cancer therapies

Inflammatory / Infectious Disease



Supervillain cells show which patients go to ICU with autoimmune response


Single Cell Proteomics Rapidly Establishing Advanced Medicine Leadership



¹ By 2020 revenue. ² Based on the National Cancer Institute's list of Comprehensive Cancer Centers.

Superhero Cell Biology Drives Large Advanced Medicine Opportunity

Wave of proteomics drives targeted & clinically relevant superhero cell biology




~5.5K
APPLICABLE
THERAPEUTIC
PROGRAMS ¹

20K
INSTRUMENT
OPPORTUNITY ¹

\$12B ²
TAM

¹ Consulting research. ² Based on management estimates

Unique and Large Impact on Human Health Create Large, High Need Markets



¹ Based on management estimates.

Accessible, Automated Proteomic Workflow is Key to Adoption & Usage

CUMULATIVE
INSTRUMENTS IN THE
FIELD¹



SAMPLES:
MANY CELL TYPES
AND PROTOCOLS



Cryopreserved Samples

INSTRUMENT:
AUTOMATED
FUNCTIONAL
PROTEOMICS HUB




AUTOMATED
ANALYTIC
SOFTWARE:
ACCESSIBLE
INSIGHTS



¹ Through Q4 2021.

The Superhuman Cell Library: The Proteomic Complement To The Genomic Cell Atlas


Key categories you can explore



A New Library of Proteomically Active Cells to Fight all of Disease



Proprietary Single-Cell Proteomic Barcoding Platform: Powerful Biology



Single Cell Proteomics


Larger "Superhuman Cell Library" + Panels =
Comprehensiveness

Leveraging Duomic for first
Connected Functional
Multi-Omic Biology

CAR-T Engineering Unlocked with Single Cell Proteomics



PREDICTS RESPONSE AND RELAPSE



Development Question from Leaders at Stanford:

What are we missing by ignoring the pre-infusion cytokine signatures of critical cell products?

Predictive Answer:

In a CD19 and CD22 bispecific CAR study, researchers using our platform showed that certain cytokine production was associated with early signs of response to CAR-T therapies or signs of relapse.

Reflection:


"Results suggest that engineering iterations should be guided by careful studies of single-cell CAR polyfunctionality incorporating cytokine production as a critical quality attribute."¹

**nature
medicine**

Predictive Durability of SC Proteomics is Accelerating Cancer Immunology



PREDICTS LONG TERM THERAPY RESPONSE



Predicting Survival in Cancer Immunology:


In a 38 patient metastatic melanoma study sponsored by Bristol Myers Squibb and Nektar Therapeutics, where the patients underwent checkpoint inhibitor and IL-2 agonist therapy. Our platform identified that a blood-based biomarker correlated with patient response and progression-free survival.

Reflection on Earlier Information Provided:

IsoPlexis has shown unique correlations with its single-cell cytokine biomarker with survival in multiple solid tumor studies with trials/therapies.

Journal of Clinical Oncology
An American Society of Clinical Oncology Journal

Duomic: Sequencing The Superhero Cells For A New Era Of Discovery



Single Cell Is Evolving To Leverage Clinically Relevant Proteome

PAST AND PRESENT Cell Type Identification Through SC -Omics

Single-Cell Uni -Omics

- SC RNA-seq
- SC ATAC-seq

Single-Cell Multi -Omics

- SC RNA seq + surface proteomics
- SC RNA-seq + ATAC-seq



isoplexis



PRESENT AND IMMINENT Cell Functional Elucidation Through Functional SC -Omics

Functional Single-Cell -Omics

- SC secretomics
- SC metabolomics
- SC intracellular proteomics
- SC transcriptomics + proteomics

"... Over the past 5 years, we have been really **focused on elucidating cellular heterogeneity and building cell atlases of human tissues** through single-cell RNA-seq ..."


- Core Director & Principal Investigator

"... The next era of single-cell -omics will focus on adding a **functional dimension to our gene expression analyses**. Intracellular proteomics, for example, accomplishes just that ..."


- Research Scientist, Major University

Duomic: How We Capture The Genetic Drivers of Superhero Cells


LEVERAGE CORE SINGLE-CELL PLATFORM




PROTEOME DETECTED AND TRANSCRIPTOME CAPTURED



SEQUENCE DETECTED




PROTEIN + SEQUENCING LINKED, PER CELL



An Integrated Roadmap & Large Opportunity

\$34B
Long Term
TAM¹



¹ Based on management estimates.

153 Foundational Patents Issued and Filed Underpins Continued Expansion

KEY PROTEOMIC PLATFORMS, TECHNOLOGIES, AND APPLICATION AREAS



IsoLight



IsoSpark



IsoSpeak



Single-Cell
Sequencing
& Protein



Single-Cell
Secretome



Single-Cell
Intracellular
Proteome



Single-Cell
Metabolome



CodePlex
Secretome



CodePlex
Intracellular
Proteome



CodePlex
Metabolome

- Automated Instrumentation and Software
- Single-Cell and High Multiplex Proteomics
- End to End Multi-omics Analysis
- Advanced Analytics

153
PROTEOMICS,
SEQUENCING,
AND SYSTEM
PATENTS

- Proteomic Barcoding
- DNA/RNA Sequencing
- High Throughput Single-Cell Sequencing + Proteomics
- Cellular Capture
- Chip Design and Fabrication
- Immune Profiling and Signatures
- Single-Cell Secretomic Capture
- Single-Cell Intracellular Proteome Capture
- Single-Cell Metabolomic Capture
- Tumor Profiling and Signatures

- Bulk Proteomic Barcoding
- Small Volume Serum Analysis
- Secretomic Capture
- Intracellular Proteome Capture
- Metabolomic Capture

Seasoned Management Built to Scale



Sean Mackay
CEO and Co-founder
LAZARD



John Strahley
CFO
IRONWOOD



Jing Zhou, MD, PhD
CSO
Yale



Peter Siesel
COO
TECAN



Richard Rew
SVP General Counsel
Luminex



Verna Siu
SVP Sales Operations
SURBIOQUEST



Carrie Carter
SVP People Ops
SARAH CANNON



Patrick Paczkowski, PhD
SVP Software
Yale



Raj Khakhar
VP Finance
Thermo Fisher
SCIENTIFIC



Anthony Catalano
SVP Operations
Purifier-Bio



Michelle Reid, Ph.D.
VP Services & Support
isoplexis



Rui Zheng, PhD
SVP Innovation
ion torrent



Cynthia Turcotte, PhD
VP Applications
454
REGULONORM



Jon Chen
VP Marketing
Yale



John H Leamon, PhD
SVP R&D Integration
isoplexis

LEADERSHIP BUILT TO SCALE:

Continued additions to global leadership team from leading Life Science Tools companies – built to scale growth

COMMERCIAL GROWTH:

Team built around senior leadership with track record in genomic, proteomic, and other med tech applications

GLOBAL FOCUS:

Directors in major global regions, with leading distribution partners in EMEA and APAC

LEADING R&D:

Track record of award winning application development and engineering, with continued velocity of launches for new applications

SCALABLE OPERATIONS:

Sustained growth of operational excellence, with experienced med tech leadership



isoplexis

© 2021 ISOPLEXIS | ALL RIGHTS RESERVED
For Research Use Only. Not for Use in Diagnostic Procedures.

Appendix 1: Superhero Cells In Leading Clinical Journals On Unique Single-Cell Proteomics

“ Our results suggest that engineering iterations should be guided by careful studies of single-cell CAR polyfunctionality incorporating cytokine production as a critical quality attribute ”

SC PROTEOMICS AS FUTURE OF
CAR-T ENGINEERING

- Nature Medicine, July 2021

Spiegel, J.Y., Patel, S., Muffly, L. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. *Nat Med* 27, 1419–1431 (2021)

“ We assessed the polyfunctional strength index (PSI), which is an indicator of the number of cells capable of secreting multiple types of cytokines. As PSI reflects the ability of a T cell to carry out multiple functions, it is recognized as a metric for the potency of cell therapy and for the efficacy of vaccines. ”

SC PROTEOMICS AS FUTURE OF
SOLID TUMOR IMMUNE MEDICINES

- Nature Medicine, August 2021

Creelan, B.C., Wang, C., Teer, J.K. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nat Med* 27, 1410–1418 (2021).


Appendix 2: Revealing the Genetic Drivers of Potentially Resistant Tumor Cells

First of its kind Duomic data presented at AGBT

HIGHLY ACTIVE "SUPERVILLAIN" PROTEOMIC SUBSET

Associated Most Strongly
with These Expressed Genes
($p < 0.01$):

- MGAT4B
- MRPL23
- ACAA2
- RAD21
- VPS28
- JTB
- SYNGR2
- KAT6A
- IRGQ
- MAPKAPK3



*All displayed genes had differential expression between the two cell subsets (p value < 0.05)

